14th April 2023. Leiden-based Dutch start-up OncoLize has closed a US$ 1.7 million first round to extend their preclinical success with a localized drug delivery system to treat Pancreatic- and Lung cancer. The round was Read more…
15th December 2022 – The USPTO has granted the patent application valid by RCSI covering the OncoLize technology. This broad base patent describes the composition-of-matter and various formulations and applications essential to the oncology business Read more…
20th December 2022 OncoLize has joined forces with a small but highly specialized consortium around the department of Engineered Therapeutics led by prof. dr. Jai Prakash from the University of Twente in the Netherlands. The Read more…
Mike de Leeuw was invited to write an expert column in a special feature of ‘Het Financieel Dagblad’ covering a.o. oncology development in the Netherlands. You can read the column here.
OncoLize will join the Dutch trade mission to China, hosted by our Prime Minister Mark Rutte and several cabinet members. OncoLize features prominent in the Life Sciences and Health group, visiting Beijing (9-10), Guangzhou (11), Read more…
OncoLize participated in the neuro-oncology symposium held in Maastricht, NL on the evening of the 11th January 2018. Links were explained between the grade of Glioma’s, eplileptic seizures and molecular biomarkers that predict low grade Read more…
“The award winning pitch by Oncolize clearly explained the unmet needs, the solution and the potential for patients, doctors and investors”. On the 11th & 12th of December 2017 the 11th European Venture Contest Finals Read more…